Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.

Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.